Ignite Creation Date:
2024-05-05 @ 4:57 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00350181
Status:
COMPLETED
Last Update Posted:
2021-09-23
First Post:
2006-07-05
Brief Title:
Sirolimus Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative Matched Related Donor HCT
Sponsor:
Stanford University
Organization:
Stanford University
Study Overview
Official Title:
Sirolimus and Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative Matched Related Donor Hematopoietic Cell Transplantation
Status:
COMPLETED
Status Verified Date:
2021-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
GVHD prophylaxis of sirolimus and mycophenolate mofetil for patients undergoing matched related allogeneic transplant for acute and chronic leukemia MDS high risk NHL and HL
Detailed Description:
To explore the novel combination of sirolimus and mycophenolate mofetil MMF as graft versus host disease GVHD prevention in HLA matched related donor blood or marrow transplantation BMT This study will report the toxicities associated with this drug combination and also explore possible correlations between specific blood cell types and antibody production during this therapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 6112 | OTHER | Stanford IRB | None |
| 97168 | OTHER | None | None |
| BMT184 | OTHER | None | None |